









市场行情
/
股票
/
nasdaq-cvac
/

CureVac NV

CVAC

4.300USD

-0.010-0.23%

收盘 12/26, 16:00（美东）报价延迟15分钟

968.24M总市值

8.85市盈率 TTM



CureVac NV

4.300

-0.010-0.23%

概览公司财务分析

概览

公司

财务

分析

关于 CureVac NV 公司

CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

CureVac NV简介



公司代码CVAC

公司名称CureVac NV

上市日期Aug 14, 2020

CEOZehnder (Alexander)

员工数量825

证券类型Ordinary Share

年结日Aug 14

公司地址Friedrich-Miescher-Str. 15

城市TUEBINGEN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Germany

邮编72076

电话49707198830

网址https://www.curevac.com/

公司代码CVAC

上市日期Aug 14, 2020

CEOZehnder (Alexander)

CureVac NV公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Baron Jean Stephenne

Independent Chairman of Supervisory Board

40.49K

+141.65%

Dr. Mathias Hothum, Ph.D.

Member of the Supervisory Board

29.31K

+170.24%

Mr. Craig A. Tooman

Independent Member of the Supervisory Board

27.79K

+187.92%

Mr. Michael Brosnan

Independent Member of the Supervisory Board

19.75K

+371.79%

Mr. Axel-Sven Malkomes

Chief Financial Officer

Dr. Klaus Schollmeier, Ph.D.

Independent Member of the Supervisory Board

Dr. Malte Greune, Ph.D.

Chief Operating Officer, Member of the Management Board

Dr. Debra Barker, M.D.

Member of the Supervisory Board

Dr. Alexander Zehnder, M.D.

Chief Executive Officer, Member of the Management Board

Dr. Myriam Mendila, M.D.

Chief Scientific Officer, Member of the Management Board

名称

名称/职务

职务

持股

持股变动

Mr. Baron Jean Stephenne

Independent Chairman of Supervisory Board

40.49K

+141.65%

Dr. Mathias Hothum, Ph.D.

Member of the Supervisory Board

29.31K

+170.24%

Mr. Craig A. Tooman

Independent Member of the Supervisory Board

27.79K

+187.92%

Mr. Michael Brosnan

Independent Member of the Supervisory Board

19.75K

+371.79%

Mr. Axel-Sven Malkomes

Chief Financial Officer

Dr. Klaus Schollmeier, Ph.D.

Independent Member of the Supervisory Board

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

Switzerland

1.06M

85.06%

Belgium (Country)

186.00K

14.94%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月16日周二

持股股东

股东类型

持股股东

占比

Glazer Capital, LLC

2.02%

Alpine Associates Management Inc.

1.02%

Qube Research & Technologies Ltd

0.76%

Bill & Melinda Gates Foundation

0.70%

AQR Capital Management, LLC

0.44%

其他

95.06%

持股股东

占比

Glazer Capital, LLC

2.02%

Alpine Associates Management Inc.

1.02%

Qube Research & Technologies Ltd

0.76%

Bill & Melinda Gates Foundation

0.70%

AQR Capital Management, LLC

0.44%

其他

95.06%

股东类型

持股股东

占比

Hedge Fund

4.03%

Investment Advisor/Hedge Fund

2.87%

Investment Advisor

1.64%

Research Firm

0.89%

Foundation

0.70%

Pension Fund

0.16%

Bank and Trust

0.13%

Individual Investor

0.09%

Sovereign Wealth Fund

0.05%

其他

89.45%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

242

23.52M

11.47%

+45.36K

2025Q3

254

23.47M

13.08%

+8.57M

2025Q2

251

14.62M

11.55%

+3.90M

2025Q1

235

10.71M

11.20%

-14.51M

2024Q4

236

10.78M

11.68%

-1.77M

2024Q3

244

12.54M

12.61%

-3.08M

2024Q2

263

15.56M

13.23%

-3.38M

2024Q1

281

18.95M

13.33%

-10.95M

2023Q4

300

23.60M

17.13%

-11.99M

2023Q3

318

35.42M

18.08%

-1.78M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Glazer Capital, LLC

594.85K

0.26%

+594.85K

Jun 30, 2025

Alpine Associates Management Inc.

1.97M

0.88%

+1.97M

Jun 30, 2025

Qube Research & Technologies Ltd

1.18M

0.53%

+1.18M

Jun 30, 2025

Bill & Melinda Gates Foundation

1.57M

0.7%

-28.77K

-1.80%

Sep 30, 2024

Water Island Capital, LLC

957.03K

0.42%

+957.03K

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

580.38K

0.26%

-17.75K

-2.97%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

AltShares Merger Arbitrage ETF

1.3%

Virtus LifeSci Biotech Clinical Trials ETF

0.65%

NYLI Merger Arbitrage ETF

0.57%

Global X Genomics & Biotechnology ETF

0.56%

ProShares Ultra Nasdaq Biotechnology

0.15%

Invesco Nasdaq Biotechnology ETF

0.11%

SPDR S&P International Small Cap ETF

0.05%

iShares Biotechnology ETF

0.04%

iShares MSCI Europe Small-Cap ETF

0.04%

iShares MSCI EAFE Small-Cap ETF

0.02%

AltShares Merger Arbitrage ETF

占比1.3%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.65%

NYLI Merger Arbitrage ETF

占比0.57%

Global X Genomics & Biotechnology ETF

占比0.56%

ProShares Ultra Nasdaq Biotechnology

占比0.15%

Invesco Nasdaq Biotechnology ETF

占比0.11%

SPDR S&P International Small Cap ETF

占比0.05%

iShares Biotechnology ETF

占比0.04%

iShares MSCI Europe Small-Cap ETF

占比0.04%

iShares MSCI EAFE Small-Cap ETF

占比0.02%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

CureVac NV的前五大股东是谁？



CureVac NV 的前五大股东如下：
Glazer Capital, LLC持有股份：594.85K，占总股份比例：0.26%。
Alpine Associates Management Inc.持有股份：1.97M，占总股份比例：0.88%。
Qube Research & Technologies Ltd持有股份：1.18M，占总股份比例：0.53%。
Bill & Melinda Gates Foundation持有股份：1.57M，占总股份比例：0.70%。
Water Island Capital, LLC持有股份：957.03K，占总股份比例：0.42%。